Background and Purpose- Intravenous thrombolysis with r-tPA (recombinant tissue-type plasminogen activator) is associated with improved early functional outcome after stroke, but its long-term effects are less understood. We aimed to determine the association between r-tPA and 1-year outcomes after stroke. Methods- We used the Ontario Stroke Registry to identify patients diagnosed with ischemic stroke between 2002 and 2013 in Ontario, Canada, their baseline characteristics, and whether they received r-tPA. We used propensity score methods to match patients treated with r-tPA to nontreated patients. The primary outcome was 1-year home-time, defined as the number of days spent outside of any healthcare institutions in the first 365 days after the index date of admission. Secondary outcomes were admission to a nursing home and all-cause mortality in the first year. Outcomes were determined using linked administrative data. We used paired tests to compare mean home-time days and Cox proportional hazards models for mortality and nursing home admission to estimate hazard ratios and 95% CI. Results- All 4449 patients treated with r-tPA in the registry were matched to nontreated patients. Compared with nontreated patients, those treated with r-tPA experienced more time at home in the first year (mean±SD was 248.9 days±137.2 treated versus 239.4 days±139.0 nontreated, =0.005) and were less likely to be admitted to nursing homes (9.4% treated versus 12.2% nontreated; hazard ratio, 0.84; 95% CI, 0.78-0.91). One-year all-cause mortality was similar between the 2 groups (13.2% treated versus 12.4% nontreated; hazard ratio, 1.07; 95% CI, 0.96-1.20). Conclusions- Despite similar mortality, patients who received r-tPA spent more time at home and were less likely to require nursing home admission in the first year after stroke compared with nontreated patients, suggesting long-term benefits and safety of this treatment.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1161/STROKEAHA.119.026922 | DOI Listing |
Medicina (Kaunas)
December 2024
Department of Internal Medicine II-Division of Nephrology, "Victor Babeș" University of Medicine and Pharmacy, 300041 Timisoara, Romania.
Hepatitis C virus (HCV) infection is a major global public health concern, particularly in hemodialysis (HD) patients. This study aims to evaluate the demographic, clinical, and laboratory characteristics of HCV-positive patients undergoing HD and assess the long-term impact of direct-acting antivirals (DAAs) on patient outcomes. Moreover, a narrative review aims to summarize the current knowledge regarding HCV treatment in HD patients.
View Article and Find Full Text PDFFront Biosci (Landmark Ed)
December 2024
Department of Immunology, Institute of Biomedical Research Universidad Nacional Autónoma de México, UNAM, 04510 Mexico City, Mexico.
Background: Multiple sclerosis (MS) is a demyelinating, neuroinflammatory, progressive disease that severely affects human health of young adults. Neuroinflammation (NI) and demyelination, as well as their interactions, are key therapeutic targets to halt or slow disease progression. Potent steroidal anti-inflammatory drugs such as methylprednisolone (MP) and remyelinating neurosteroids such as allopregnanolone (ALLO) could be co-administered intranasally to enhance their efficacy by providing direct access to the central nervous system (CNS).
View Article and Find Full Text PDFJ Cosmet Dermatol
December 2024
La Roche Posay Laboratoire Dermatologique, Levallois-Perret, France.
Background: Post-inflammatory hyperpigmentation (PIHP) predominantly affects patients with melanin-rich skin, significantly impacting them psychosocially due to more frequent and severe pigmentary changes. In this study, the efficacy of a novel depigmenting agent 2-mercaptonicotinoyl glycine (Melasyl) in a dermocosmetic (DC) serum formulation is assessed as a stand-alone treatment of PIHP without sunscreen.
Materials And Methods: Thirty-two Mauritian subjects aged 18-50 years of phototype IV-VI presenting mild acne (GEA2) and moderate to severe PIHP (PAHPI > 10) participated in this study.
J Med Life
October 2024
Department of Doctoral Sciences, Faculty of Medicine and Pharmacy, University of Oradea, Oradea, Romania.
Apical periodontitis (AP) is a common dental condition that can be influenced by diabetes mellitus. This study aimed to investigate the impact of type 2 diabetes mellitus (T2DM) on the prevalence and severity of AP, considering the adequacy of endodontic treatments. A total of 180 patients selected based on specific dental criteria from a private clinic in Oradea, Romania, were included in this study.
View Article and Find Full Text PDFOrthod Craniofac Res
December 2024
Department of Orthodontics and Dentofacial Orthopedics, Dental School/Medical Faculty, University of Bern, Bern, Switzerland.
The primary objective was to systematically assess the prevalence, incidence and risk factors of WSLs with orthodontic treatment. The secondary objective was to compare the prevalence of WSLs between conventional fixed appliances (CFA) and other appliances, as well as with no treatment. PubMed, Scopus, Web of Science, LILACs, Virtual Health Library and Cochrane CENTRAL were searched.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!